NAPA, Calif., April 17 /PRNewswire-FirstCall/ -- Senetek PLC (OTC
Bulletin Board: SNKTY), a Life Sciences company engaged in the development
of technologies that target the science of healthy aging, today announced
it has engaged Riley-Nacht LLC, a global brand development and marketing
company focused on the skincare industry to support the commercialization
of Senetek's dermatological products.
Riley-Nacht was founded by Les Riley, Dr. Sergio Nacht and Brian Riley.
Riley-Nacht is known for their expertise in all phases of brand development
and will play a key role in Senetek's dermatological product marketing
program.
Les Riley stated, "Pyratine-6(TM) is a next generation skin care
technology. Based on a review of the clinical data, we are enthusiastic
about working with Senetek on its commercial development. Pyratine-6(TM)
has the potential for extraordinary success in the global skin care
markets."
Les Riley has over thirty years of experience in the pharmaceutical and
skincare industries. Prior to founding Riley-Nacht, Mr. Riley was President
of Cardinal Health, Topical Technologies, a company formed through the
acquisition of Advanced Polymer Systems that integrated existing Cardinal
Health technologies and infrastructure. Mr. Riley has also served as
President and CEO of TriStrata Incorporated, and President and CEO of
NeoStrata Company Inc., a subsidiary of TriStrata. Mr. Riley spent
seventeen years with Johnson & Johnson Co., Inc. as President of the
Dermatological Division, where he was responsible for operations, including
sales and marketing, licensing and acquisitions, and new product
development.
Mr. Riley was granted membership in the American Academy of Dermatology
in 2004, in recognition of his years of service and contribution to
advancing the specialty of dermatology.
Dr. Sergio Nacht is a skin biologist with 35 years of academic,
industrial and commercial experience. Prior to the founding of Riley-Nacht,
Dr. Sergio Nacht was Senior Vice President of Dermatology and Skin Care at
Cardinal Health, Topical Technologies, where he was responsible for the
overall expansion of Topical Technologies with emphasis on dermatological
and skincare technologies and for technical business development worldwide.
Dr. Nacht also occupied key scientific and R&D positions at
Richardson-Vicks/ Procter & Gamble and at Alza Corporation.
Dr. Nacht is a member of several professional societies, including the
American Academy of Dermatology, The Dermatology Foundation and The Society
of Cosmetic Chemists. He has co-authored more than 50 scientific papers and
book chapters and holds fifteen U.S. patents.
Brian Riley has over ten years experience in the sales, marketing and
distribution of skin and personal health products. Mr. Riley created and
developed Boulder Consulting, a marketing firm focused on business
planning, marketing, and product development for clients in the skincare
industry including Boston University, Department of Dermatology, and
Rejuvenation Centers, Ltd.
Prior to founding Boulder Consulting, Mr. Riley partnered with leading
executives in the industry to form DermFirst Inc., with clients including
Ortho-Neutrogena, Allergan Skincare, ICN Pharmaceuticals, ProCyte, Inc.,
Genesis Pharmaceutical, and NeoStrata Company. Mr. Riley was also involved
in the development of an anti-aging treatment system marketed through
direct response television.
As a marketer, Mr. Riley had responsibility at Medicis Pharmaceutical
Corporation for the launch and overall management of TxSystems, a new
business unit specializing in non-prescription dermatologicals for
improving the appearance of aging skin. Mr. Riley was also involved in the
launch and/or marketing of the Medicis prescription and OTC products,
including Lustra(R), Esoterica(R), Dynacin(R), Triaz(R), Novacet(R),
Loprox(R), Lidex(R), and Synalar(R).
Frank Massino, Chairman and Chief Executive Officer of Senetek stated,
"The team of Riley and Nacht bring unparalleled expertise to our program
for the accelerated development of Senetek's substantial dermatological
portfolio. Their extensive networks and affiliations with current thought
leaders in dermatology will help define the course of our marketing efforts
in this area."
About Senetek PLC
Senetek PLC (OTCBB: SNKTY) is a Life Sciences company engaged in the
development of breakthrough technologies that target the science of healthy
aging. The Company's extensive research collaborations have resulted in a
strong pipeline of patented compounds and products with broad therapeutic
applications and a leading presence in dermatology. Senetek collaborates
with established specialty pharmaceutical companies in the final
development and marketing of its proprietary products, most recently
resulting in the development of the best-selling anti-aging product sold in
the North American physician market.
For more information, visit the company's website at
http://www.senetekplc.com.
This news release contains statements that may be considered
'forward-looking statements' within the meaning of the Private Securities
Litigation Reform Act. Forward-looking statements by their nature involve
substantial uncertainty, and actual results may differ materially from
those that might be suggested by such statements. Important factors
identified by the Company that it believes could result in such material
differences are described in the Company's Annual Report on Form 10-K for
the year 2007. However, the Company necessarily can give no assurance that
it has identified or will identify all of the factors that may result in
any particular forward-looking statement materially differing from actual
results, and the Company assumes no obligation to correct or update any
forward-looking statements which may prove to be inaccurate, whether as a
result of new information, future events or otherwise.
SOURCE Senetek PLC
 back to top
Related links:
http://www.senetekplc.com
CONTACT:
Marjorie Hays, Vice President, Communications
of Senetek PLC, +1-707-226-3900, ext. 102
|
